Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Wirshing, D. A. Articles by Wirshing, W. C. Search for Related Content PubMed Citation Articles by Wirshing, D. A. Articles by Wirshing, W. C. Schizophrenia Spectrum Disorders Other Neuroleptics

Risperidone in Treatment-Refractory Schizophrenia

OBJECTIVE: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. METHOD: Sixty-seven medication-unresponsive subjects were randomly assigned to treatment with risperidone (N=34) or haloperidol (N=33). After a 3–7 day-placebo washout period, there was a 4-week, double-blind, fixed-dose comparison trial that was followed by a 4-week, flexible-dose phase. Measures of clinical change were quantified by standard psychopathologic and neuromotor instruments. RESULTS: Risperidone demonstrated clinical efficacy superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. Risperidone did not show any advantage over haloperidol after an additional 4 weeks. Overall improvement on the BPRS at 4 weeks was significantly better for the risperidone group (24%) than for the haloperidol group (11%). Risperidone-treated subjects were significantly less likely than haloperidol-treated subjects to require concomitant anticholinergic medication after 4 weeks (20% versus 63%); they also had significantly less observable akathisia (24% versus 53%) and significantly less severe tardive dyskinesia. Baseline characteristics that correlated significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia. CONCLUSIONS: Risperidone was better tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. Positive psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful predictors of subsequent response to risperidone.

This article has been cited by other articles:

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, February 26, 2008; (2008) sbn005v1. [Abstract] [Full Text] [PDF]

				S. M. Silverstein Integrating Jungian and Self-Psychological Perspectives Within Cognitive-Behavior Therapy for a Young Man With a Fixed Religious Delusion Clinical Case Studies, June 1, 2007; 6(3): 263 - 276. [Abstract] [PDF]

				S. Ranjan, P. S Chandra, S. K Chaturvedi, S. C Prabhu, and A. Gupta Atypical Antipsychotic-Induced Akathisia with Depression: Therapeutic Role of Mirtazapine Ann. Pharmacother., April 1, 2006; 40(4): 771 - 774. [Abstract] [Full Text] [PDF]

				G. Catalano, J. W. Grace, M. C. Catalano, M. J. Morales, and L. M. Cruse Acute Akathisia Associated With Quetiapine Use Psychosomatics, August 1, 2005; 46(4): 291 - 301. [Abstract] [Full Text] [PDF]

				W. Aichhorn, U. Weiss, J. Marksteiner, G. Kemmler, T. Walch, G. Zernig, R. Stelzig-Schoeler, C. Stuppaeck, and C. Geretsegger Influence of age and gender on risperidone plasma concentrations J Psychopharmacol, July 1, 2005; 19(4): 395 - 401. [Abstract] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Focus, January 1, 2004; 2(1): 59 - 67. [Abstract] [Full Text] [PDF]

				M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials Focus, January 1, 2004; 2(1): 111 - 121. [Abstract] [Full Text] [PDF]

				A. H. Cheung, C. S. Dewa, and D. Wasylenki Economic Grand Rounds: Impact on Cost Estimates of Differences in Reports of Service Use Among Clients, Caseworkers, and Hospital Records Psychiatr Serv, October 1, 2003; 54(10): 1328 - 1330. [Full Text] [PDF]

				J. M. Davis, N. Chen, and I. D. Glick A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564. [Abstract] [Full Text] [PDF]

				S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling Amisulpride, an Unusual ""Atypical"" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials Am J Psychiatry, February 1, 2002; 159(2): 180 - 190. [Abstract] [Full Text] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Am J Psychiatry, February 1, 2002; 159(2): 255 - 262. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us